Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Sho, M. et al.

Masayuki Sho, Toshihiro Tanaka, Takatsugu Yamada, Takeo Nomi, Takahiro Akahori, Jin Doh, Ichiro Yamato, Daisuke Hokuto, Hideyuki Nishiofuku, Nagaaki Marugami, Hiromichi Kanehiro, Kimihiko Kichikawa, Yoshiyuki Nakajima,

Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer.

BACKGROUND/PURPOSE: It has been reported recently that adjuvant gemcitabine prolonged postoperative disease-free survival in patients with resectable pancreatic cancer. However, the efficacy was limited and further studies are required to improve the prognosis. In particular, postoperative hepatic recurrence often occurs even after gemcitabine treatment. METHODS: We are currently trying to evaluate the efficacy of postoperative combination therapy of high-dose 5-fluorouracil (5-FU) arterial infusion with systemic gemcitabine. Patients received weekly high-dose 5-FU through the hepatic artery using a port-catheter system (1000 mg/m(2) for 5 h) plus concurrent systemic gemcitabine (1000 mg/m(2)). RESULTS: Thirty-one patients were enrolled and 29 patients (94%) completed the scheduled adjuvant chemotherapy. The toxicity was acceptable and this regimen was well feasible as an outpatient treatment. At the time of analysis, 21 patients (68%) had recurrence. Local recurrence was most frequently observed, in 43% of the patients with recurrence. On the other hand, hepatic recurrence developed in only 2 patients (10%). The 1-year disease-free rate and overall survival rate were 62.9 and 100%, respectively. CONCLUSION: Our novel adjuvant strategy had a significant beneficial effect on early hepatic recurrence and may have the potential to prolong the overall survival of pancreatic cancer patients.[1]

References

Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. Sho, M., Tanaka, T., Yamada, T., Nomi, T., Akahori, T., Doh, J., Yamato, I., Hokuto, D., Nishiofuku, H., Marugami, N., Kanehiro, H., Kichikawa, K., Nakajima, Y. J. Hepatobiliary. Pancreat. Sci (2011) [Pubmed]

Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.